What Aro Biotherapeutics does

Aro Biotherapeutics is a clinical-stage biotechnology company developing tissue-targeted genetic medicines for rare genetic and immune-mediated diseases. Its proprietary Centyrin platform is built on small, exceptionally stable engineered human proteins designed to enable receptor-specific delivery of therapeutic payloads, including siRNA, antisense oligonucleotides, proteins, and small molecules, to disease tissues. The platform was discovered at Janssen by co-founders Dr. Susan Dillon and Dr. Karyn O'Neil, and the company operates under an exclusive worldwide license for Centyrin protein therapeutics.

The company's lead clinical candidate, ABX1100, is a first-in-class CD71 receptor-binding Centyrin conjugated to a siRNA targeting GYS1 mRNA in muscle tissue for the treatment of late-onset Pompe disease (LOPD). In a Phase 1b trial in nine LOPD patients, ABX1100 achieved approximately 62% sustained GYS1 mRNA knockdown in quadriceps muscle through Week 10 and a mean forced vital capacity improvement of approximately 2.5% at 5 months, with no serious adverse events, infusion reactions, or discontinuations. ABX1100 has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation. The company is also advancing Centyrin-siRNA conjugate programs for autoimmune disorders, supported by a 2020 collaboration with Ionis Pharmaceuticals for cell-specific delivery of antisense oligonucleotides.

Aro Biotherapeutics is pre-revenue and monetizes its pipeline exclusively through future commercialization of approved therapeutics, with no disclosed pricing or licensing revenue to date. The company is headquartered in Philadelphia, Pennsylvania, and has raised approximately $142.5 million in cumulative equity funding across a 2018 seed round, a 2021 Series A, and a 2023 Series B, with continuous investment from Johnson & Johnson Innovation – JJDC. The go-to-market motion is a traditional clinical-stage biotech model: advancing candidates through clinical development at trial sites in the US and Canada, with planned distribution through specialty pharmacies and hospital procurement channels upon regulatory approval.

Name

Aro Biotherapeutics

Legal name

Aro Biotherapeutics

Website

https://arobiotx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Aro Biotherapeutics is a clinical-stage Philadelphia-based biotechnology company developing tissue-targeted genetic medicines using its proprietary Centyrin protein platform. Its lead candidate ABX1100 delivers siRNA to muscle for late-onset Pompe disease, with pipeline expansion into autoimmune disorders.

Ownership category

akta.pro rank

Product category

Genetic Medicines / RNA Therapeutics (Tissue-Targeted)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Tissue-targeted therapeutics
• SiRNA drug delivery
• Protein engineering platform
• Rare disease medicines
• Centyrin technology platform

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing a pipeline of Centyrin-based therapeutic candidates. Revenue will be generated through commercialization of approved therapeutics for rare genetic and immune-mediated diseases once clinical development is completed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Aro Biotherapeutics develops tissue-targeted genetic medicines using its proprietary Centyrin platform — small, stable, engineered human proteins that are conjugated to oligonucleotide payloads (primarily siRNA) to enable receptor-specific delivery to disease tissues. The lead clinical product, ABX1100, is a CD71 Centyrin–GYS1 siRNA conjugate for late-onset Pompe disease. The company is also advancing Centyrin-siRNA conjugate programs for autoimmune disorders and maintains a partnered pipeline for antisense oligonucleotide delivery.

Product overview

Aro Biotherapeutics is a clinical-stage biotechnology company pioneering tissue-targeted genetic medicines. The company's proprietary Centyrin Platform serves as the foundational technology, providing small, stable, engineered human proteins for receptor-specific delivery of therapeutic payloads. The lead clinical product is ABX1100, a CD71 Centyrin-GYS1 siRNA conjugate for late-onset Pompe disease (LOPD), which recently reported positive Phase 1b topline results demonstrating approximately 62% GYS1 mRNA knockdown and functional lung function improvement. The pipeline includes Centyrin-siRNA conjugate programs targeting autoimmune disorders and other diseases. The company also offers an Oligonucleotide-Based Therapeutics platform for extrahepatic delivery of siRNA and antisense oligonucleotides using Centyrin-mediated targeting.

Differentiator

Problem solved

Functional benefit

Products and services

• ABX1100 ABX1100 is a muscle-targeted, first-in-class CD71 receptor-binding Centyrin conjugated to a siRNA targeting GYS1 mRNA. It is the company's lead clinical candidate for the treatment of late-onset Pompe disease (LOPD), a rare neuromuscular disorder caused by genetic deficiency of acid alpha-glucosidase (GAA) leading to toxic glycogen buildup in muscle tissue. Phase 1b topline results demonstrated approximately 62% sustained GYS1 mRNA knockdown in quadriceps muscle through Week 10, mean forced vital capacity (FVC) improvement of approximately 2.5% at 5 months, reduction in muscle damage and glycogen load biomarkers, and an excellent safety profile with no serious adverse events or infusion reactions. It has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation, and represents a novel substrate reduction approach to Pompe disease with the potential for quarterly or less frequent dosing versus current 6-hour IV enzyme replacement infusions multiple times per month.
• Centyrin-siRNA Conjugate Pipeline (Autoimmune Disorders)
• Partnered Centyrin-Oligonucleotide Programs (Ionis Collaboration)

Quantifiable outcome

• Approximately 62% sustained GYS1 mRNA knockdown in quadriceps muscle tissue through Week 10 in LOPD patients
• +3 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Ionis Pharmaceuticals (Option Exercise)coreStrategic or Co-development Partner · 6 October 2020Ionis exercised an option to advance the collaboration with Aro focused on cell-specific delivery of antisense oligonucleotides.
• Ionis PharmaceuticalscoreStrategic or Co-development Partner · 9 January 2020Aro Biotherapeutics and Ionis entered a licensing and collaboration agreement in January 2020 focused on cell-specific delivery of antisense oligonucleotides. Ionis participated in Series A financing as existing investor. The collaboration was advanced with an option exercise in October 2020.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alnylam Pharmaceuticals: Leading siRNA therapeutics company with approved products (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio) and a broad pipeline targeting liver and other tissues. Directly comparable as a clinical/commercial-stage siRNA developer, though Alnylam is far more advanced and focused primarily on GalNAc-conjugated hepatic delivery.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with multiple conjugate-based delivery platforms (TRiM) targeting extrahepatic tissues including muscle. Highly comparable as a direct competitor in tissue-targeted RNA delivery and a frequent benchmark for novel siRNA delivery technologies.
• Ionis Pharmaceuticals: Leader in antisense oligonucleotide (ASO) therapeutics with multiple approved products and a large pipeline. Directly comparable as an RNA-targeted therapeutics developer and is also an active collaboration partner and investor in Aro Biotherapeutics.
• Avidity Biosciences: Clinical-stage biotechnology company developing antibody-oligonucleotide conjugates (AOCs) for muscle diseases including myotonic dystrophy, Duchenne muscular dystrophy, and FSHD. Closely comparable to Aro in targeting muscle with conjugate-based RNA delivery technology.
• Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotides for rare diseases including Duchenne muscular dystrophy and Huntington's disease. Comparable as an RNA-targeted therapeutics developer with similar platform-driven approach to extrahepatic and CNS targets.

Emerging players

• Amicus Therapeutics: Specialty biotechnology company focused on rare metabolic diseases including Pompe disease (with AT-GAA in late-stage development). Directly comparable as a Pompe disease competitor and broader lysosomal storage disorder peer.
• Skyhawk Therapeutics: Clinical-stage company developing small molecules that modulate RNA splicing, with partnerships across multiple large pharmaceutical companies. Comparable as an emerging RNA-targeted therapeutics developer with a distinct but adjacent modality.

Broad incumbents

• Genzyme (Sanofi): Established leader in enzyme replacement therapy for Pompe disease (alglucosidase alfa/Myozyme/Lumizyme). Comparable as the incumbent standard of care in LOPD and the primary competitor that ABX1100 would need to displace or complement.
• BioMarin Pharmaceutical: Established rare disease biotechnology company with multiple approved enzyme replacement and gene therapy products. Comparable as a broader rare-disease specialty therapeutics peer with similar regulatory and commercialization dynamics.
• Regenxbio: Clinical and commercial-stage gene therapy company developing AAV-based treatments for rare diseases. Comparable as a rare-disease genetic medicines developer using a different delivery modality (AAV vs. Centyrin conjugates) for similar target indications.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AroBioTx
• LinkedInlinkedin.com/company/aro-biotherapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aro Biotherapeutics